PDCD1 and non-small cell lung carcinoma: In one investigation, the analysis of metabolites in plasma from NSCLC patients before and after nivolumab treatment using liquid chromatography-MS (LC-MS) or gas chromatography-MS (GC-MS) showed that a combination of four metabolites could effectively predict the therapeutic effect of the PD-1 inhibitor (139).